Form 4: ACADIA Legal Officer Exercises RSUs, Sells Shares for Tax

ACADIA Pharmaceuticals' EVP, Chief Legal Officer, Jennifer J. Rhodes, exercised restricted stock units and subsequently sold a portion of the acquired common stock to cover tax obligations.

Summary

• Jennifer J. Rhodes, EVP, Chief Legal Officer, SEC of ACADIA PHARMACEUTICALS INC, reported transactions involving the company's common stock.
• On February 6, 2026, Rhodes acquired 12,944 shares of common stock through the exercise of restricted stock units (RSUs) at a price of $0 per share.
• These RSUs represent a contingent right to receive one share of common stock, with 50% vesting on February 6, 2026, and 25% vesting on each of February 6, 2027, and February 6, 2028.
• Following this acquisition, Rhodes beneficially owned 14,559 shares, which includes 595 shares acquired on May 15, 2025, via an employee stock purchase plan.
• On February 9, 2026, Rhodes sold 6,950 shares of common stock at a weighted average price of $23.38 per share, with individual sales ranging from $23.38 to $23.40.
• These sales were mandatory to cover withholding taxes and tax-related items associated with the vesting of the restricted stock units and were executed under a Rule 10b5-1(c) plan.
• After the sale, Rhodes beneficially owns 7,609 shares of ACADIA PHARMACEUTICALS INC common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine insider transactions related to executive compensation and tax obligations, which typically do not indicate a change in company fundamentals or executive sentiment regarding future performance.

Positives

• The vesting of restricted stock units indicates the fulfillment of compensation milestones for a key executive.
• The acquisition of 12,944 shares through RSU exercise at a $0 cost basis reflects a significant equity grant to a senior officer.

Negatives

• The sale of 6,950 shares, while for tax purposes, reduces the direct equity holdings of a key executive.

Future Outlook

The filing primarily details past transactions and scheduled future vesting dates for restricted stock units, but does not provide broader forward-looking statements or guidance on company performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, detailing insider transactions. These transactions, particularly sales for tax purposes following RSU vesting, are common occurrences for executives in the biotechnology and pharmaceutical sectors, reflecting standard compensation practices rather than a change in company fundamentals or executive sentiment.

Comparison to Industry Standards

• The exercise of restricted stock units and subsequent sale of shares for tax withholding purposes is a standard practice for executive compensation in the pharmaceutical industry, aligning with common equity incentive plans seen at companies like Biogen Inc. (BIIB) or Gilead Sciences, Inc. (GILD).
• The use of a Rule 10b5-1 plan for the sale indicates a pre-arranged transaction designed to avoid accusations of insider trading, a common corporate governance practice among executives at major pharmaceutical firms.

Related Party Transactions

• The acquisition of common stock through the exercise of restricted stock units and the subsequent sale of shares by Jennifer J. Rhodes, an EVP and Chief Legal Officer, are considered related party transactions as they involve a company insider.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even for tax purposes, slightly increases the float but is unlikely to have a material impact on share price given the relatively small volume compared to daily trading.
• Employees: The RSU vesting and subsequent tax-related sale are standard compensation practices, reinforcing the company's equity incentive programs.

Next Steps

• Additional 25% of the restricted stock units are scheduled to vest on February 6, 2027.
• The final 25% of the restricted stock units are scheduled to vest on February 6, 2028.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and tax-related sales) and does not provide new information regarding the company's operational performance, financial health, or strategic direction. Therefore, it does not warrant a change in investment recommendation. Investors should 'hold' their position based on existing fundamental analysis, as this filing offers no new catalysts for 'buy' or 'sell' decisions.

Keywords

ACADIA Pharmaceuticals, ACAD, Jennifer J. Rhodes, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Executive Compensation, Rule 10b5-1